(E)-3-acetonylidene-1-azabicyclo[2.2.2]octane

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 奎宁环
• 英文名称: (E)-3-acetonylidene-1-azabicyclo[2.2.2]octane
• 英文别名: (E)-3-acetylmethylene-1-azabicyclo[2.2.2]octane；(1E)-1-(1-azabicyclo[2.2.2]octan-3-ylidene)propan-2-one
• 化学式: C₁₀H₁₅NO
• 分子量: 165.235
• InChiKey: XVFBZAKFUWQJMY-POHAHGRESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-奎宁环酮 、 丙酮基膦酸二甲酯 在 氢氧化钾 作用下， 反应 90.0h， 生成 (E)-3-acetonylidene-1-azabicyclo[2.2.2]octane 、 (Z)-3-acetylmethylene-1-azabicyclo[2.2.2]octane
  参考文献：
  名称：

  Bioisosteric replacement strategy for the synthesis of 1-azacyclic compounds with high affinity for the central nicotinic cholinergic receptors

  摘要：

  Bioisosteric replacement of the isoxazole heterocycle in (3-methyl-5-isoxazolyl)methylene-azacyclic compounds with pyridine, oxadiazole, or an acyl group resulted in ligands with high to moderate affinity for the central nicotinic cholinergic receptors (IC50 = 2.0 to IC50 > 1000 nM) labeled by [H-3]methylcarbamylcholine. Additionally, further support of an important distance parameter for high-affinity nicotinic compounds has been provided. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(00)00063-8

文献信息

• QUINUCLIDINE DERIVATIVE
  申请人：LTT BIO-PHARMA CO., LTD.

  公开号：US20180051018A1

  公开（公告）日：2018-02-22

  Provided is a novel therapeutic agent for chronic obstructive pulmonary disease. Provided are a quinuclidine derivative and a medicament comprising the quinuclidine derivative. wherein R 1 represents a hydrogen atom, a halogen atom, a lower alkyl group, a haloalkyl group, a lower alkoxy group, or a haloalkoxy group; Y represents —C(C═O)—O—, —CH 2 —, or —CH 2 O—; m represents an integer of 1 to 5; Z represents an oxygen atom or a sulfur atom; l represents a number of 0 or 1; n represents an integer of 0 to 4; X − represents an anion; and a substituent of a quinuclidine ring represents a 1,3-bond, or 1,4-bond, provided that when m is 3, l is 1, and n is 0, R 1 represents a halogen atom, a lower alkyl group, a haloalkyl group, a lower alkoxy group, or a haloalkoxy group.

  提供了一种用于慢性阻塞性肺疾病的新型治疗剂。 提供了一种喹诺啉衍生物和包括该喹诺啉衍生物的药物。 其中，R1代表氢原子、卤原子、低碳基团、卤代烷基团、低碳氧基团或卤代氧基团；Y代表—C(C═O)—O—、—CH2—或—CH2O—；m代表1到5的整数；Z代表氧原子或硫原子；l代表0或1的数字；n代表0到4的整数；X−代表阴离子；喹诺啉环的取代基代表1,3-键或1,4-键，但当m为3，l为1，n为0时，R1代表卤原子、低碳基团、卤代烷基团、低碳氧基团或卤代氧基团。
• NOVEL SUBSTITUTED AZACYCLIC OR AZABICYCLIC COMPOUNDS
  申请人：NOVO NORDISK A/S

  公开号：EP0871627A1

  公开（公告）日：1998-10-21
• [EN] NOVEL SUBSTITUTED AZACYCLIC OR AZABICYCLIC COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES AZACYCLIQUES OU AZABICYCLIQUES A SUBSTITUTION
  申请人：NOVO NORDISK A/S

  公开号：WO1997011073A1

  公开（公告）日：1997-03-27

  (EN) The present invention relates to therapeutically active heterocyclic compounds, to methods for their preparation and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating diseases in the central nervous system related to malfunctioning of the nicotinic cholinergic system.(FR) Cette invention a trait à des composés hétérocycliques à activité thérapeutique, à des procédés permettant leur préparation ainsi qu'à des compositions pharmaceutiques les contenant. Ces nouveaux composés se révèlent utiles dans le traitement de maladies du système nerveux central liées à un dysfonctionnement du système cholinergique nicotinique.
• Bioisosteric replacement strategy for the synthesis of 1-azacyclic compounds with high affinity for the central nicotinic cholinergic receptors
  作者：Preben H. Olesen、Janne E. Tønder、John Bondo Hansen、Holger C. Hansen、Karin Rimvall

  DOI：10.1016/s0968-0896(00)00063-8

  日期：2000.6

  Bioisosteric replacement of the isoxazole heterocycle in (3-methyl-5-isoxazolyl)methylene-azacyclic compounds with pyridine, oxadiazole, or an acyl group resulted in ligands with high to moderate affinity for the central nicotinic cholinergic receptors (IC50 = 2.0 to IC50 > 1000 nM) labeled by [H-3]methylcarbamylcholine. Additionally, further support of an important distance parameter for high-affinity nicotinic compounds has been provided. (C) 2000 Elsevier Science Ltd. All rights reserved.